jhve
JHVEPhoto / shutterstock.com
29 May 2020AmericasRory O'Neill

FDA warns of ‘grave’ knock-on effects from Eagle decision

The  US Food and Drug Administration (FDA) has warned a US Court of Appeals for the DC Circuit decision awarding market exclusivity to  Eagle Pharmaceuticals for a cancer drug will have “grave” consequences for patient access.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
11 May 2020   The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.
Big Pharma
18 December 2019   US-based Eagle Pharmaceuticals has dropped its patent infringement and antitrust claims against Eli Lilly.
Americas
1 July 2021   Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.

More on this story

Americas
11 May 2020   The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.
Big Pharma
18 December 2019   US-based Eagle Pharmaceuticals has dropped its patent infringement and antitrust claims against Eli Lilly.
Americas
1 July 2021   Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.

More on this story

Americas
11 May 2020   The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.
Big Pharma
18 December 2019   US-based Eagle Pharmaceuticals has dropped its patent infringement and antitrust claims against Eli Lilly.
Americas
1 July 2021   Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.